ArticleFrontiers in pharmacology2025
Xiaozhi Yufa decoction ameliorates androgenetic alopecia through inhibition of MAPK signaling and regulation of lipid metabolism.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Androgenetic alopecia represents the most common form of progressive hair loss, with current treatments showing limitations in efficacy or tolerability. Xiaozhi Yufa decoction (XZYFD), a Traditional Chinese Medicine formulation composed of 13 herbal medicines, has shown clinical potential in treating hair loss. Methods: Network pharmacology analysis identified active compounds and potential targets of XZYFD, with molecular docking evaluating compound-target interactions. A testosterone propionate-induced mouse model was established to assess XZYFD's therapeutic efficacy. Treatment effects were evaluated through hair regrowth assessment, histological examination, serum biochemical analysis, and molecular pathway investigation. Results: Network pharmacology identified 57 overlapping targets between XZYFD and androgenetic alopecia, with enrichment in MAPK signaling and lipid metabolism pathways. Conclusion: XZYFD ameliorates androgenetic alopecia through simultaneous modulation of androgen metabolism, MAPK signaling, and SREBP-1-mediated lipid metabolism, with potential advantages for patients with metabolic dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.